Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Three More Leading Medical Centres Join Clinical Trial for Congenital Heart Disease

Published: Tuesday, July 17, 2012
Last Updated: Tuesday, July 17, 2012
Bookmark and Share
The Hospital for Sick Children is core lab for VMS ™ analysis.

VentriPoint Diagnostics Ltd announces the Children's Hospital of Colorado, The Children's Hospital of Philadelphia (CHOP), and The Hospital for Sick Children (SickKids) in Toronto have joined the multi-centre clinical trial studying the most common form of congenital heart disease, Tetralogy of Fallot or Blue-Baby Syndrome.

"We are very excited to be installing the VentriPoint Diagnostic System in our echocardiography lab in the Heart Institute at Children's Hospital Colorado and to be participating in the FDA trial. We feel this system has the potential to tremendously impact how we manage our patients with heart disease and we look forward to putting this system into everyday use", stated Dr. Bruce (Biff) F. Landeck II, assistant professor of pediatric cardiology.

The Tetralogy of Fallot clinical trial is designed to show substantial equivalency between the gold-standard MRI method, and the 2D-ultrasound VMS™ technique. Based on advice from the FDA, the study has been designed to collect images at multiple sites and to analyze them at core labs. Nationwide Children's Hospital in Columbus Ohio is the lead center for the study and the MRI core lab and the University of Nebraska has been announced as a second image-collection site. Along with the three new image-collection sites, we are also announcing SickKids will be the core lab for the VMS analysis.

To date, with only two centres, the study has enrolled 40 patients in the clinical trial, which is designed to complete 75 evaluable cases. With five centres now enrolling, the study is expected to be completed and submitted to the FDA in 3Q12 in support of regulatory approval through a 510(k) process by the end of the year.

"Enrollment has been slow as patients are reluctant to have an MRI for research purposes. Only one out of twenty patients approached agrees to volunteer. In addition, it takes several weeks to schedule the MRI," stated Dr. George Adams, CEO of VentriPoint, "This clinical experience reinforces the need for the VMS™ approach, which takes 5 minutes of patient time compared to over an hour in the MRI and can be done immediately by a sonographer without the need for patient sedation."

The VMS™ is for investigational use only in the United States and is approved for clinical use in Canada and Europe.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!